Related Experiment Videos
Evaluation of chemotherapy before limb-sparing surgery for osteosarcoma
International Orthopaedics
|January 1, 1992
Summary
Preoperative chemotherapy for osteosarcoma can shrink tumors before limb-sparing surgery. Intravenous cisplatin demonstrated superior tumor control compared to other agents, supporting its use in treatment protocols.
Area of Science:
- Oncology
- Orthopedic Surgery
- Chemotherapy
Background:
- Osteosarcoma treatment often involves neoadjuvant chemotherapy to reduce tumor burden.
- Limb-sparing surgery aims for complete tumor resection while preserving limb function.
- Preventing distant metastases is a critical goal in osteosarcoma management.
Purpose of the Study:
- To evaluate the efficacy of different preoperative chemotherapy protocols for osteosarcoma.
- To determine the optimal chemotherapy regimen for facilitating limb-sparing surgery.
- To assess tumor response through clinical, radiological, and histological parameters.
Main Methods:
- Fifteen patients with osteosarcoma received one of six distinct preoperative chemotherapy protocols.
- Tumor size was assessed clinically and radiologically before and after chemotherapy.
- Histological examination of resected specimens and serum alkaline phosphatase levels were analyzed.
Main Results:
- Intravenous cisplatin, administered three times preoperatively at three-week intervals, showed the greatest tumor control.
- Cisplatin's efficacy surpassed that of adriamycin or methotrexate in the evaluated protocols.
- Tumor response was correlated with clinical, radiological, and histological findings.
Conclusions:
- Preoperative chemotherapy is crucial for managing osteosarcoma, enabling limb-sparing surgery.
- Intravenous cisplatin appears to be a highly effective agent for preoperative osteosarcoma treatment.
- Prompt surgical intervention combined with postoperative chemotherapy is recommended for optimal outcomes.